CG Oncology director sells 1,000 shares at $74.54

CG Oncology, Inc. (CGON) director Leonard E. Post reported an option exercise and related share sale.

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) director Leonard E. Post reported an option exercise and related share sale. On 2026-08-14 he exercised a fully vested director stock option for 1,000 shares of common stock at an exercise price of $0.60 per share, then sold 1,000 shares of common stock at $74.54 per share in a transaction reported as a sale in the open market or a private transaction. After the exercise, he held 104,077 director stock options directly. The sale was carried out under a Rule 10b5-1 trading plan adopted on March 5, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,000 shares ($74K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider POST LEONARD E

Role Director

Sold 1,000 shs ($75K)

Approx. gross sale proceeds $75K

Approx. exercise cost $600.00

Approx. pre-tax spread $74K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy) F2	1,000	$0.00	$0.00
Exercise	Common Stock	1,000	$0.60	$600.00
Sale	Common Stock F1	1,000	$74.54	$75K

Holdings After Transaction: Director Stock Option (right to buy) — 104,077 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
2. F2. Fully vested

Key Figures

Options Exercised: 1,000 shares Exercise Price: $0.60 per share Shares Sold: 1,000 shares +3 more

6 metrics

Options Exercised 1,000 shares Director stock options exercised into common stock on 2026-08-14

Exercise Price $0.60 per share Exercise price of director stock option converted on 2026-08-14

Shares Sold 1,000 shares Common stock sold on 2026-08-14

Sale Price $74.54 per share Price for sale of CGON common stock on 2026-08-14

Options Held After Transaction 104,077 shares Director stock options directly owned after reported option exercise

10b5-1 Plan Adoption Date March 5, 2026 Rule 10b5-1 trading plan governing the reported sale

Key Terms

Rule 10b5-1 trading plan, Director Stock Option (right to buy), derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CGON director Leonard E. Post report on this Form 4?

Leonard E. Post reported exercising 1,000 director stock options at $0.60 and selling 1,000 common shares at $74.54 on 2026-08-14, all held directly as reported in the filing.

Was the CGON insider sale by Leonard E. Post under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Leonard E. Post on March 5, 2026, indicating the transactions followed a pre-established plan.

At what prices did Leonard E. Post exercise and sell CGON shares?

He exercised director stock options at an exercise price of $0.60 per share and sold 1,000 shares of CG Oncology common stock at a reported price of $74.54 per share on 2026-08-14.

How many CGON director stock options does Leonard E. Post hold after these transactions?

After the reported option exercise, Leonard E. Post directly held 104,077 director stock options in CG Oncology, Inc., as indicated by the total shares following the derivative transaction field in the Form 4 data.

What types of securities were involved in Leonard E. Post’s CGON Form 4 filing?

The filing involves a Director Stock Option (right to buy), which is a derivative security, and the underlying Common Stock of CG Oncology, Inc., including both the acquisition via exercise and the subsequent sale of shares.

Is Leonard E. Post a director or officer of CG Oncology, Inc. (CGON)?

Leonard E. Post is reported as a director of CG Oncology, Inc. in the Form 4. He is not listed as an officer and is not identified as a ten percent owner in the reported data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:31 PM Accepted by SEC EDGAR 08/18/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		M		1,000	A	$0.6	1,000	D
Common Stock	08/14/2026		S(1)		1,000	D	$74.54	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	08/14/2026		M			1,000	(2)	07/08/2028	Common Stock	1,000	$0	104,077	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

2. Fully vested

	/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)